WASHINGTON, DC, May 6, 2015 – The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, today announced the release of its first-ever quarterly data report, offering an in-depth look at sector trends and metrics from the months January through March 2015.
Using information provided by ARM’s data partner Informa, the quarterly report details sector-specific statistics compiled from more than 580 leading companies worldwide, including total financings, corporate partnerships and acquisitions, clinical trials, data events and ARM’s current regulatory priorities. Major trends emerging from the first quarter 2015 include ongoing interest in the oncology space, with significant focus on CAR-T and other adoptive T cell therapies, as well as increasing and expanded interest in the sector from large pharmaceutical companies.
The report also includes commentary from ARM member company executives, including Avalanche Biotechnologies, Inc.; Audentes Therapeutics, Inc.; GE Healthcare; Kite Pharma; Mesoblast Limited, Pluristem Therapeutics Inc; and Voyager Therapeutics, Inc.
“The beginning of 2015 continued this sector’s impressive 2014 performance,” said Morrie Ruffin, managing director of ARM. “We are seeing impressive growth overall compared to first quarter 2014, and we expect sustained institutional and private investor interest in the sector as the year unfolds.”
Highlighted findings from the Q1 report include:
• Companies in the combined regenerative medicine and advanced therapies field raised more than $2.7 billion in the first quarter of 2015, a 135 percent increase compared to the same quarter last year. The report also includes additional information by technology focus area and financing type.
• There were 486 clinical trials underway at the end of first quarter 2015, with 150 in Phase I, 288 in Phase II and 48 in Phase III. More than one third of current clinical trials are focused on oncology and more than one tenth are in the cardiovascular space.
• ARM’s current regulatory priorities remain focused on facilitating a clearer path to market for regenerative medicine and advanced therapies products; the U.S. Regenerative Medicine Promotion Act and coordinated federal policymaking; sector-supportive reimbursement models and payment structure; anticipated guidelines from the EU Committee for Advanced Therapies; and focus on early market access opportunities through ARM’s relationship with Japan’s FIRM.
ARM will provide updates to this information with additional reports to be released after the close of each quarter throughout the year, tracking sector performance and identifying emerging trends.
For more information, please visit alliancerm.org or contact ARM’s Communications Director Lyndsey Scull at firstname.lastname@example.org.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.